/
Oncology
Pancreatic Adenocarcinoma
56
Pipeline Programs↗
47
Active Trials↗
46
Companies Involved↗
Pancreatic Adenocarcinoma is a moderately active landscape with 56 programs across 46 companies. The most active players are Novartis, CG Pharmaceuticals, Inc, Candel Therapeutics, Inc.. 4 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical6
Phase 19
Phase 237
Phase 34
Approved
No programs
Analysis
Modality Breakdown
75%
Small molecule
39 of 52 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 52 classified programs, each share of the total. Modality classified for 98% of 56 pipeline programs.
Analysis
Trial Status
160
clinical trials
Completed67 · 42%
Terminated25 · 16%
Recruiting22 · 14%
Active, not recruiting20 · 13%
Unknown status13 · 8%
Withdrawn8 · 5%
Other5 · 3%
Clinical Trials
Trial Activity
160 trials
A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma
Recruiting·—·Phase 2·NCT05624918·38 enrolled
Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma
Recruiting·—·Phase 2·NCT04543071·10 enrolled
Chemotherapy + Anakinra in Patients With Pancreatic Adenocarcinoma (PDAC)
Recruiting·—·Phase 2·NCT04926467·24 enrolled
9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)
Recruiting·—·Phase 1·NCT06896188·12 enrolled
Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma
Recruiting·—·Phase 2·NCT05241249·37 enrolled
Page 1 of 11
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)